35,652 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Bought by Neo Ivy Capital Management

Neo Ivy Capital Management purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 35,652 shares of the biopharmaceutical company's stock, valued at approximately $744,000.

Several other large investors have also recently added to or reduced their stakes in CPRX. Farther Finance Advisors LLC lifted its position in Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after acquiring an additional 1,495 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in Catalyst Pharmaceuticals by 13.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company's stock valued at $8,710,000 after buying an additional 50,888 shares during the last quarter. Spire Wealth Management boosted its holdings in Catalyst Pharmaceuticals by 1,342.9% in the 4th quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company's stock valued at $301,000 after purchasing an additional 13,429 shares during the period. Sanctuary Advisors LLC boosted its holdings in Catalyst Pharmaceuticals by 91.5% in the 4th quarter. Sanctuary Advisors LLC now owns 59,447 shares of the biopharmaceutical company's stock valued at $1,241,000 after purchasing an additional 28,407 shares during the period. Finally, Nilsine Partners LLC bought a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at about $700,000. 79.22% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on CPRX shares. Robert W. Baird increased their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Stephens reaffirmed an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Finally, HC Wainwright reissued a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $32.29.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 200,000 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $23.68, for a total value of $4,736,000.00. Following the completion of the transaction, the insider now directly owns 68,873 shares in the company, valued at $1,630,912.64. The trade was a 74.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares of the company's stock, valued at $4,333,200.72. This represents a 25.04% decrease in their position. The disclosure for this sale can be found here. Insiders sold 351,879 shares of company stock worth $8,214,815 over the last three months. 10.40% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX traded up $0.35 on Tuesday, hitting $24.84. 937,199 shares of the stock were exchanged, compared to its average volume of 1,105,488. The stock has a fifty day moving average price of $23.57 and a two-hundred day moving average price of $22.56. The firm has a market capitalization of $3.03 billion, a P/E ratio of 21.05, a P/E/G ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a 52-week low of $14.75 and a 52-week high of $26.16.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.